Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Four topical regimens for vitiligo
IRCT20220117053743N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clobetasol, propylene glycol, aspirin, copper sulfate and methoxsalen in Vitiligo (4 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Perifollicular pigmentation improvement. Started Mar 2022; status: completed.
02
Drugs
clobetasolpropylene glycolaspirincopper sulfatemethoxsalen
03
Conditions
Vitiligo
Beyond the preview
Go deeper on IRCT20220117053743N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220117053743N2.